XT
VIR icon

XTX Topco’s Vir Biotechnology VIR Stock Holding History

XTX Topco’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-66,942
Closed -$600K – 4748
2026
Q1 		$600K Buy
66,942
+6,864
+11% +$54.7K 0.01% 1858
2025
Q4 		$362K Sell
60,078
-79,818
-57% -$475K 0.01% 1900
2025
Q3 		$799K Buy
+139,896
New +$715K 0.04% 720
2025
Q1 		– Sell
-24,085
Closed -$177K – 3169
2024
Q4 		$177K Buy
+24,085
New +$190K 0.01% 1605
2024
Q3 		– Sell
-48,399
Closed -$431K – 2649
2024
Q2 		$431K Buy
+48,399
New +$464K 0.04% 732
2023
Q4 		– Sell
-44,205
Closed -$414K – 2193
2023
Q3 		$414K Buy
+44,205
New +$630K 0.07% 514
2023
Q1 		– Sell
-8,096
Closed -$205K – 1681
2022
Q4 		$205K Sell
8,096
-3,358
-29% -$82.3K 0.04% 830
2022
Q3 		$221K Buy
+11,454
New +$291K 0.05% 724

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

XTX Topco's VIR Position: Q2 2026 in Review

XTX Topco sold out of Vir Biotechnology (VIR) in Q2 2026, closing a stake of 66,942 shares — an estimated $600K sold.

XTX Topco first reported a position in VIR in Q3 2022 and held it in 8 quarters. The position peaked at $799K in Q3 2025. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • XTX Topco reported no remaining Vir Biotechnology position as of Q2 2026 after selling out during the quarter.
  • XTX Topco sold 66,942 Vir Biotechnology shares in Q2 2026, an estimated $600K.
  • XTX Topco first reported a position in Vir Biotechnology in Q3 2022 and held it in 8 quarters.
  • XTX Topco's Vir Biotechnology position peaked at $799K in Q3 2025.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.